Position in UTHR
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$3,293,242
-$178,062 QoQ
Shares Held
6,078
+3.8% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#302
of 874 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 17%
Shared 0%
None 83%
Common Shares in UTHR Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Focus Partners Wealth holds $57,760,663 across 23 Drug Manufacturers - Specialty & Generic names. UTHR ranks #5 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
77,994 | $13,145,108 | |
| 2 | ZTS |
Zoetis Inc.
|
180,366 | $12,961,100 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
679,950 | $10,899,598 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
67,843 | $7,526,502 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
This page
|
6,078 | $3,293,242 | |
| 6 | ALKS |
Alkermes plc.
|
41,596 | $2,179,630 | |
| 7 | HLN |
Haleon plc
|
221,287 | $2,064,607 | |
| 8 | TEVA |
Teva Pharmaceutical Industries Ltd
|
35,560 | $1,204,772 |
All Filings in UTHR
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,293,242 | 6,078 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $3,471,304 | 5,854 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,234,852 | 6,639 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,165,403 | 2,780 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $679,295 | 2,364 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $449,457 | 1,458 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $676,394 | 1,917 | Shares | Sole | 2025-05-20 | |
| 2024-09-30 | $302,447 | 844 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||